Efficacy and biomarker analysis of carboplatin plus taxanes neoadjuvant chemotherapy in triple-negative breast cancer: A prospective multicenter cohort study
机构：[1]Chinese Acad Med Sci & Peking Union Med Coll, Natl Canc Ctr, Dept Med Oncol, Natl Clin Res Ctr Canc,Canc Hosp, Beijing, Peoples R China[2]Capital Med Univ, Xuanwu Hosp, Dept Gen Surg, Ctr Thyroid & Breast Surg, Beijing, Peoples R China首都医科大学宣武医院[3]Hebei Univ, Affiliated Hosp, Dept Med Oncol, Baoding, Peoples R China河北大学附属医院[4]Hebei Key Lab Canc Radiotherapy & Chemotherapy, Baoding, Hebei, Peoples R China[5]Genecast Biotechnol Co Ltd, Wuxi, Jiangsu, Peoples R China[6]Chinese Acad Med Sci & Peking Union Med Coll, Natl Canc Ctr, Beijing, Peoples R China[7]Chinese Acad Med Sci, Dept Gen Surg, Dept Thyroid Breast Hernia Surg, Beijing Hosp,Natl Ctr Gerontol,Inst Geriatr Med,B, Beijing, Peoples R China[8]Chinese Acad Med Sci & Peking Union Med Coll, Natl Canc Ctr, Canc Hosp, Natl Clin Res Ctr Canc, Beijing, Peoples R China
第一作者机构：[1]Chinese Acad Med Sci & Peking Union Med Coll, Natl Canc Ctr, Dept Med Oncol, Natl Clin Res Ctr Canc,Canc Hosp, Beijing, Peoples R China
推荐引用方式(GB/T 7714)：
Chen Xi,Xiu Meng,Kang Hua,et al.Efficacy and biomarker analysis of carboplatin plus taxanes neoadjuvant chemotherapy in triple-negative breast cancer: A prospective multicenter cohort study[J].JOURNAL OF CLINICAL ONCOLOGY.2024,42(16):
APA：
Chen, Xi,Xiu, Meng,Kang, Hua,Zhang, Yan,Yang, Hua...&Zhang, Pin.(2024).Efficacy and biomarker analysis of carboplatin plus taxanes neoadjuvant chemotherapy in triple-negative breast cancer: A prospective multicenter cohort study.JOURNAL OF CLINICAL ONCOLOGY,42,(16)
MLA：
Chen, Xi,et al."Efficacy and biomarker analysis of carboplatin plus taxanes neoadjuvant chemotherapy in triple-negative breast cancer: A prospective multicenter cohort study".JOURNAL OF CLINICAL ONCOLOGY 42..16(2024)
医学